Study record · Semaglutide (injectable)

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)

MACE occurred in 6.5% vs 8.0%; HR 0.80 (95% CI 0.72–0.90).

Key result

MACE occurred in 6.5% vs 8.0%; HR 0.80 (95% CI 0.72–0.90).

Study designRandomized, double-blind, placebo-controlled cardiovascular outcomes trial

PhasePhase 3 / outcomes

PopulationAdults ≥45 with established cardiovascular disease and overweight/obesity, without diabetes

Sample size17604

RouteSubcutaneous

Regimen / exposure2.4 mg once weekly

DurationMean exposure 34.2 months; follow-up 39.8 months

ComparatorPlacebo

Primary endpoint / questionMajor adverse cardiovascular events

Safety resultPermanent discontinuation due to adverse events 16.6% vs 8.2%.

Key limitationsSecondary prevention population; not generalisable to low-risk healthy adults; product discontinuation higher with semaglutide.

Registry / identifierNCT03574597